Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Neuroendocrine × Standard of Care × 90 days × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 12 Colorectal Neoplasms 12 Breast Neoplasms 10 Prostatic Neoplasms 9 Carcinoma, Non-Small-Cell Lung 8 Lung Neoplasms 7 Neoplasm Metastasis 6 Hematologic Neoplasms 6 Hematopoietic and Lymphatic System Neoplasm 5 Urinary Bladder Neoplasms 4 Triple Negative Breast Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Ovarian Neoplasms 4 Breast Carcinoma In Situ 4 Sarcoma 3 Motor Activity 3 Leukemia, Myeloid, Acute 3 Stomach Neoplasms 2 Pathologic Complete Response 2 Osteosarcoma 2 Myelodysplastic Syndromes 2 Multiple Myeloma 2 Melanoma 2 Lymphoma, Follicular 2 Lymphedema 2 Hemangiosarcoma 2 Head and Neck Neoplasms 2 Frailty 2 Fallopian Tube Neoplasms 2 Carcinoma, Squamous Cell 2

Interventions

atezolizumab 3 Etoposide 2 Cisplatin 2 zimberelimab 1 tivozanib 1 durvalumab 1 cabozantinib 1 belinostat 1 Temozolomide 1 Standard of Care 1 Positron Emission Tomography Computed Tomography 1 Nivolumab 1 Magnetic Resonance Imaging 1 Ipilimumab 1 Immunoglobulin G 1 Disulfides 1 Carboplatin 1 Capecitabine 1 CTLA-4 Antigen 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07337447 2026-01-13

REWENEC 01

Hospices Civils de Lyon

Phase 2 Not yet recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡